The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Notably, the enobosarm 3mg + semaglutide was the best dose with a >99% mean relative reduction in loss of lean mass (p <0.001). Enobosarm 6mg + semaglutide dose was not better than the Enobosarm ...

Notably, the enobosarm 3mg + semaglutide was the best dose with a >99% mean relative reduction in loss of lean mass (p <0.001). Enobosarm 6mg + semaglutide dose was not better than the Enobosarm 3mg + ...

Veru Inc.--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 ----Topline efficacy and safety data for Phase 2b extension maintenance study expected ...

Interest in weight-loss products continues to surge as calls come for a faster rollout of treatments on the NHS. Research by ...

Despite ongoing financial challenges, the market reacted positively to the company’s cost-cutting measures and strategic focus on drug development. Veru Inc. continues to navigate its financial ...

They deserve a raise, KEEP THEM. The pharmacy located at 5969 Lankershim Blvd. North Hollywood, CA 91601 Manager ** assisted me and Medi-Cal as well as My Dr office with above and beyond ...

Ultrafine particle meter-dose inhalers (MDIs) have not demonstrated superior asthma control or improved safety over older MDIs. All of the inhaled corticosteroids demonstrate efficacy with once ...